Table 5 Alterations in biomarkers induced by chemotherapy in breast cancer patients remaining free of VTE within 3 months of chemotherapy

From: Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer

Coagulation marker Prechemotherapy (n) Day 1 (post-chemotherapy) (n) Day 4 (post-chemotherapy) (n) Day 8 (post-chemotherapy) (n) 3 months (post-chemotherapy) (n)
APTT s, mean (CI) 23.1 (22.6–23.6) (94) 21.8 (21.3–22.2) (97) 21.5 (21.1–21.9) (96) 21.8 (21.3–22.3) (99) 21.0 (20.5–21.5) (91)
PT s, mean (CI) 11.7 (11.6–11.9) (94) 11.9 (11.7–12.0) (97) 11.7 (11.6–11.9) (96) 11.8 (11.7–12.0) (99) 11.5 (11.3–11.7) (91)
TAT μg ml−1, geometric mean (CI) 5.7 (4.0–8.0) (17) 7.1 (4.4–11.3) (16) 6.7 (4.5–10.2) (16) 5.8 (3.8–8.6) (16) 5.6 (2.8–11.2) (13)
Fibrinogen g l−1, mean(CI) 3.4 (3.2–3.7) (87) 3.2 (2.9–3.4) (90) 3.1 (2.8–3.3) (89) 3.4 (3.1–3.6) (97) 3.9 (3.6–4.2) (83)
D-dimer ng ml−1, geometric mean (CI) 756.6 (655.9–872.7) (110) 787.1 (677.5–914.5) (104) 746.3 (640.7–869.1) (104) 748.4 (646.1–867.0) (105) 747.2 (632.5–882.7) (100)
Platelet count × 109 l−1 mean (CI) 311.6 (295.2–328.0) (111) 302.4 (283.4–321.4) (89) 262.5 (248.1–277.0) (97) 239.0 (223.4–254.5) (106) 302.5 (279.6–325.5) (102)
TF μg ml−1, geometric mean (CI) 104.4 (82.0–133.1) (110) 109.1 (84.5–140.9) (106) 91.7 (71.1–118.2) (103) 91.2 (71.8–115.7) (105) 95.3 (74.3–122.1) (99)
CP mU, geometric mean (CI) 31.6 (29.4–33.9) (100) 36.5 (34.1–39.1) (98) 34.6 (32.3–37.1) (93) 32.4 (30.1–34.9) (97) 31.2 (29.0–33.6) (91)
pVEGF μg ml−1, geometric mean (CI) 15.4 (13.5–17.7) (108) 14.5 (12.9–16.4) (104) 16.0 (13.7–18.7) (101) 20.2 (18.0–22.7) (103) 21.9 (18.8–25.5) (97)